إعلان
إعلان
MLTX
MoonLake Immunotherapeutics Class A Ordinary Shares
14.34
USDبرعاية
+3.05
+27.03%
٠٨ يناير, ١٦:٠٠ UTC -5
مغلق
قبل الإفتتاح
15.11
+0.77
+5.37%
تقارير أرباح MLTX
النسبة الإيجابية المفاجئة
MLTX تفوق 8 من 14 آخر التقديرات.
57%
التقرير التالي
بيانات التقرير القادم
٢٤ فبراير ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
--
/-$1.00
التغير الضمني من Q3 25 (Revenue/ EPS)
--
/-9.09%
التغير الضمني من Q4 24 (Revenue/ EPS)
--
/+38.89%
MoonLake Immunotherapeutics Class A Ordinary Shares earnings per share and revenue
On ٠٥ نوفمبر ٢٠٢٥, MLTX reported earnings of -1.10 USD per share (EPS) for Q3 25, missing the estimate of -0.89 USD, resulting in a -22.75% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +4.54% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 18 المحللين forecast an EPS of -1.00 USD, with revenue projected to reach -- USD, implying an نقصان of -9.09% EPS, and زيادة of 0.00% in Revenue from the last quarter.
الأسئلة الشائعة
What were MoonLake Immunotherapeutics Class A Ordinary Shares's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, MoonLake Immunotherapeutics Class A Ordinary Shares reported EPS of -$1.10, missing estimates by -22.75%, and revenue of $0.00, 0% as expectations.
How did the market react to MoonLake Immunotherapeutics Class A Ordinary Shares's Q3 2025 earnings?
The stock price moved up 4.54%, changed from $10.13 before the earnings release to $10.59 the day after.
When is MoonLake Immunotherapeutics Class A Ordinary Shares expected to report next?
The next earning report is scheduled for ٢٤ فبراير ٢٠٢٦.
What are the forecasts for MoonLake Immunotherapeutics Class A Ordinary Shares's next earnings report?
Based on 18
المحللين, MoonLake Immunotherapeutics Class A Ordinary Shares is expected to report EPS of -$1.00 and revenue of -- for Q4 2025.
Which companies are reporting earnings today?
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان